DrugsControl Media Services
DrugsControl.org

News Detail

CDSCO approves antibody for rare skin disorder in Indian adults (16-05-2024)

Mumbai, 16 May 2024: The Central Drugs Standard Control Organisation (CSDCO) on Wednesday approved Boehringer Ingelheim’s Spevigo (Spesolimab) injection, a first-in-class treatment for adults suffering from Generalised Pustular Psoriasis (GPP) flares -- a rare skin disorder......
View Details

Source : IANS
Central Drugs Standard Control Organisation (CSDCO) Boehringer Ingelheim’s Spevigo (Spesolimab) injection

Related News